Claim OwnershipSimply Oncology
Subscribed: 25Played: 378
Subscribe
© 2025 Simply Oncology
Description
Welcome to Simply Oncology.
Cancer is daunting for both patients and for clinical teams.
Dr John McGrane and Dr Michael Rowe are oncologists who want to break down the complex parts of cancer care into clear and simple sessions.
We will dive deep into the world of cancer research, patient stories and the latest cancer breakthroughs.
Simply Oncology will have patient focused episodes along with episodes that allow anyone with an interest in oncology to stay up to date.
We hope you join us as we unpick all parts of cancer.
John & Mike
78 Episodes
Reverse
Send us a text
Send us a text Join us as we return for Part 2 with the superb Dr Alison Berner. It’s Transgender Awareness Week and we discuss resources to support patients and clinicians. We discuss OUTpatients and UCATS - UK cancer and transition service.
Send us a text As we approach transgender awareness week we discuss cancer care in the transgender community with the exceptional Dr Alison Berner. 1 in 40 people aged under 30 identify as transgender in recent census. How we give support needed and signpost patients can have a huge influence on their experience of care. Alison has done so much work in this area. We learned a lot in this episode and we hope you enjoy! https://outpatients.org.uk/ https://www.wearetransplus.co.uk/uk-cancer-an...
Send us a text We return to discuss stereotactic radiotherapy (SABR) in prostate cancer with the superb Dr Alison Tree from The Royal Marsden Hospital. We discuss the findings of the TRAP study which extended time to next treatment by 6 months when SABR was used for sites of growing disease. Do we always need to change systemic therapy when only one or two sites of metastatic disease is growing??
Send us a text We are back for part 2 to finish our journey through the Gut Microbiome with the excellent Professor Monty Pal !! Few areas of cancer treatment have generated as much interest as the Gut Microbiome in recent years. We discuss work done by Monty's team on CBM588 on immunotherapy in kidney cancer. CBM 588 is a live bacterial product that is available in health shops in Japan where it is used to promote a healthy gut. Monty's team found incredible results where it improved r...
Send us a text Did you know that we have more bacterial DNA than human DNA in our bodies. This is because our guts contain trillions of bacteria and are now being thought of as another organ of the body. Join us this week as we discuss the Gut Microbiome (part 1 of 2) and its importance on drugs like immunotherapy response in cancer. We talk to none other than the excellent Professor Monty Pal from The City of Hope Hospital in California. Monty is an internationally respected kidney cancer ex...
Send us a text Did you know that the lifetime risk of prostate cancer in a black man is 1 in 4 ? That’s twice the risk of prostate cancer in a white man. Did you know that men in Scotland are twice as likely to have advanced prostate cancer compared to those in the South of England? Professor Frank Chinewungdoh is a man on a mission. He is trying to make prostate cancer testing as possible to men across all groups. He makes an argument for prostate cancer screening and measures to make ...
Send us a text We are back to finish our journey through cancer vaccines with Dr Lennard Lee. We celebrate some of the heroes of UK cancer vaccine trials from centres Big & Small. Lennard gives us all some hope for the future. We now are officially Watching This Space for more Cancer Vaccine Trial results.
Send us a text Cancer Vaccines are Here!! We talk to a man who is on a mission! Dr Lennard Lee - associate Professor at Oxford University Hospital. Lennard has a vision where we use the technologies developed in Vaccines during COVID and turn them into effective treatments for cancer. This is some space age stuff but its HERE, its EXCITING, its HAPPENING!!
Send us a text We return on our odyssey through Rectal Cancer with the amazing Professor Richard Adams from Velindre cancer Centre, Cardiff. In this episode we discuss the immunotherapy revolution in the subgroup of rectal cancer that is MSI-High. We discuss future directions in rectal cancer. We also give Richard a wish - AND HE GOES BIG!!! What a treat to have these 2 episodes with Richard!
Send us a text In this episode we venture in to a new tumour site: Colorectal Cancer. We are joined by internationally renowned oncologist Professor Richard Adams from Velindre Cancer Centre. In Part 1 we dive in to treatment of localised rectal cancer, with a comprehensive overview of the role of radiotherapy, contact brachytherapy and total neodjuvant therapy. We also explore the evolving evidence of non-operative management of rectal cancer. We look into the OPERA (EU), OPRA ...
Send us a text Biliary Tract Cancers - Cholangiocarcinomas and Gallbladder cancers are often seen as rare and aggressive cancers. 🎙️We tackle Biliary Tract Cancers with the exceptional Professor John Bridgewater. 🎙️Few people are as knowledgable & linked to a cancer as Prof Bridgewater is to cholangiocarcinoma. 🎙️Prof Bridgewater has led practice changing studies in this area and is an internationally renowned expert. 🎙️This group of cancers is more common than you think! 🎙️If you don’...
Send us a text
Send us a text We discuss Early Phase Clinical Trials with Dr Natalie Cook from the Christie Early Trials Unit. We learn how molecular profiling is shaping early phase trials and how future trials may be shaped.
Send us a text Clinical Trials are the Stepping Stones for the progress we have made over the years in the treatment of cancer. We talk to Dr Mohini Varughese who is heavily involved in clinical trials in urology and passionate about the delivery of clinical trials across oncology. We discuss: 🎙️Phase 1,2 &3 trials 💊The benefits for patients 💉The benefits for clinical teams
Send us a text Join us as we return for Part 2 of our conversation with lead medical advisor to MacMillan - Dr Anthony Cunliffe. Anthony is also a practising GP with ideas on how we can work better together - starting with how we keep our patients and GP teams up to date with our oncology letters. We talk about Performance status and why it so important to us in oncology and also how we can make life easier for people to understand our letters without extra work. The oncology letters from cli...
Send us a text How we communicate is so important in all aspects of medicine. In this special 2 part episode we look at demystifying the Language of Oncology. Our letters go to GPs and patients and we speak to Dr Anthony Cunliffe who is the medical lead for Macmillan Cancer Support and a practising GP. If you are GP or acute medic who treats cancer patients or a patient with access to your letters this is a MUST LISTEN. Also those of us oncologists wanting to make our letters useful for GP te...
Send us a text Join us for an episode looking at the role of radiotherapy in cancer treatment. We discuss the principles of radiotherapy with Dr Grant Stewart who has 20 years experience with radiotherapy treatments. This is a great episode for anyone wanting to understand the principles of radiotherapy. IF you are a patient wanting to understand your treatment or a doctor or nurse wanting to know more about radiotherapy please check this out!
Send us a text We are back again discussing stereotactic ablative body radiotherapy (SABR) with Dr Harshani Green from the Royal Marsden Hospital. Join us if : - You want to hear about the evidence from the FASTRACK II trial using renal SABR - You are a centre thinking about setting up renal SABR - You want to hear about the challenges of comparing renal SABR with surgery Will radiotherapy be able to replace cytoreductive nephrectomy in metastatic renal carcinoma? We discuss this and more (pl...
Send us a text Join us for Part 1 of our 2 part Simply Oncology podcast with Dr Harshani Green on Stereotactic Ablative Body Radiotherapy (SABR) in Renal Cell Carcinoma. We discuss the role of high precision radiotherapy treating renal cell carcinoma in those patients where an operation may not be possible. - We discuss the excellent control rates - What size of tumour can we treat? - Will we ever be able to compare Surgery versus SABR for primary renal cell carcinoma cancers?
Comments
Download from Google Play
Download from App Store
United States